Asti Corporation

Nanbu Plastics Co., Ltd.

Ono Pharmaceutical Co., Ltd.

Hamamatsu University School of Medicine

Masahiro Takigawa

Noriyuki Ogai

Akinori Inou

Hiroshi Ozawa

Takayuki Maruyama

Toshiya Kanaji

Kiyoshi Ishibashi

Nobuo Oikawa

Naohiro Seo

Akihiko Ikeda

Kenji Kabashima

The purpose of the present invention is to provide a microneedle array and a microneedle manufacturing method, which improves medical solution delivery efficiency and facilitates manufacturing. The microneedle array is provided with a first divisional element, a second divisional element to be bonded to the first divisional element, a longitudinal passage formed between the first divisional element and the second divisional element bonded to each other; and a horizontal hole, having an orifice on a lateral side and formed in a direction parallel to a bonding surface of the first divisional element with the second divisional element, and communicating to the longitudinal passage.

Microneedle array

Device for administering drug solution

The transdermal administration device of the present invention includes: a needle support with a plurality of microneedles formed at a tip portion thereof; a holder with the needle support placed therein, allowing the needle support to protrude itself therefrom and retract therein; and a cap for covering the microneedles, and further includes: a spring member placed between the needle support and the holder, for biasing the needle support in a protruding direction; an engaging portion at a base of the needle support; and an engaged portion capable of engaging the engaging portion, formed in the holder, where the engaging portion of the needle support can be locked with the engaged portion of the holder when the needle support is retracted in the holder.

Transdermal administration device

Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease. An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.

Cytotoxic T cell activator comprising EP4 agonist

Growing community of inventors

Kyoto, Japan

Masahiro Takigawa